黏液性卵巢癌的大规模平行测序分析:基因组图谱与鉴别诊断
本研究对原发性黏液性卵巢癌(MOC)进行全外显子或靶向341个癌症基因的大规模平行测序,并做免疫组化分析,发现MOC在遗传学上具有异质性,常见TP53、KRAS突变及CDKN2A/B缺失/突变,且部分病例的突变和免疫组化特征类似子宫内膜样癌或结直肠癌。研究提示检测TP53、KRAS、PIK3CA、ARID1A、POLE突变及DNA错配修复蛋白表达可能有助于MOC的诊断和治疗决策。
要点
- MOC中常见TP53(75%)、KRAS(71%)突变和/或CDKN2A/B纯合缺失/突变(33%)。
- 4例MOC的突变和免疫组化特征类似子宫内膜样癌,1例类似结直肠或子宫内膜样癌。
- confirmed primary MOCs(n=19)与HGSOCs、胃黏液癌和/或结直肠黏液癌在KRAS、TP53、CDKN2A、FBXW7、PIK3CA和/或APC突变频率上存在显著差异。
核心结论
- 研究提示,评估TP53、KRAS、PIK3CA、ARID1A和POLE突变以及DNA错配修复蛋白表达,可能有助于原发性MOC的诊断和治疗决策。
研究设计与样本
- 对原发性MOC和匹配的正常组织/血液DNA进行全外显子测序(n=9)或针对341个癌症基因的大规模平行测序(n=15)。
- 对所有病例进行雌激素受体、孕激素受体、PTEN、ARID1A/BAF250a及DNA错配修复蛋白MSH6和PMS2的免疫组化分析。
- 将MOC的突变频率与高级别浆液性卵巢癌(HGSOC)及其他部位黏液性肿瘤进行比较。
主要发现
- MOC在遗传学上具有异质性,常见TP53(75%)突变、KRAS(71%)突变和/或CDKN2A/B纯合缺失/突变(33%)。
- 尽管采用了既定的诊断标准,4例病例具有类似子宫内膜样癌的突变和免疫组化特征,1例类似结直肠或子宫内膜样癌。
- 在确认的原发性MOC(n=19)与HGSOC、胃黏液癌和/或结直肠黏液癌之间,KRAS、TP53、CDKN2A、FBXW7、PIK3CA和/或APC突变频率存在显著差异。
- 在研究的341个基因中,MOC与胰腺黏液癌之间未发现差异。
临床怎么用
- 作者认为,评估TP53、KRAS、PIK3CA、ARID1A和POLE突变以及DNA错配修复蛋白表达,可能有助于原发性MOC的诊断和治疗决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Mucinous ovarian cancer (MOC) is a rare type of epithelial ovarian cancer resistant to standard chemotherapy regimens. We sought to characterize the repertoire of somatic mutations in MOCs and to define the contribution of massively parallel sequencing to the classification of tumors diagnosed as primary MOCs. METHODS: Following gynecologic pathology and chart review, DNA samples obtained from primary MOCs and matched normal tissues/blood were subjected to whole-exome (n = 9) or massively parallel sequencing targeting 341 cancer genes (n = 15). Immunohistochemical analysis of estrogen receptor, progesterone receptor, PTEN, ARID1A/BAF250a, and the DNA mismatch (MMR) proteins MSH6 and PMS2 was performed for all cases. Mutational frequencies of MOCs were compared to those of high-grade serous ovarian cancers (HGSOCs) and mucinous tumors from other sites. RESULTS: MOCs were heterogeneous at the genetic level, frequently harboring TP53 (75%) mutations, KRAS (71%) mutations and/or CDKN2A/B homozygous deletions/mutations (33%). Although established criteria for diagnosis were employed, four cases harbored mutational and immunohistochemical profiles similar to those of endometrioid carcinomas, and one case for colorectal or endometrioid carcinoma. Significant differences in the frequencies of KRAS, TP53, CDKN2A, FBXW7, PIK3CA and/or APC mutations between the confirmed primary MOCs (n = 19) and HGSOCs, mucinous gastric and/or mucinous colorectal carcinomas were found, whereas no differences in the 341 genes studied between MOCs and mucinous pancreatic carcinomas were identified. CONCLUSIONS: Our findings suggest that the assessment of mutations affecting TP53, KRAS, PIK3CA, ARID1A and POLE, and DNA MMR protein expression may be used to further aid the diagnosis and treatment decision-making of primary MOC.
引用
- Mueller JJ, Schlappe BA, Kumar R, et al. Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses. Gynecol Oncol. 2018. PMID: 29793804. doi:10.1016/j.ygyno.2018.05.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。